10x Genomics reported second quarter 2026 revenue of $151.0 million, exceeding analyst estimates of $146.67 million. While reported revenue declined year-over-year from $172.9 million, results were impacted by a $27.3 million litigation settlement in the prior year; excluding non-recurring settlements in both periods, revenue grew 3%.
Key Highlights
- Gross margin expanded to 74% from 72% in the prior year period, aided by $2.6 million in tariff refunds and lower manufacturing costs.
- Spatial consumables revenue grew 16% year-over-year to $42.3 million, partially offsetting a sharp decline in total instrument revenue, which fell to $7.7 million from $14.5 million.
- Full-year 2026 revenue guidance was raised to a range of $610 million to $630 million, up from the previous range of $600 million to $625 million, reflecting optimism regarding the Atera platform launch.